Does Rallies show 13F holders for HALO?

Yes. Rallies tracks hedge fund and 13F ownership data for HALO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is HALO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for HALO. It does not provide personalized investment advice.

HALO (Halozyme Therapeutics, Inc.) Stock Analysis - Hedge Fund Holdings

Halozyme Therapeutics, Inc. (HALO) is a publicly traded Healthcare sector company. As of May 21, 2026, HALO trades at $69.47 with a market cap of $8.00B and a P/E ratio of 23.31. HALO moved +0.36% today. Year to date, HALO is -3.12%; over the trailing twelve months it is +29.06%. Its 52-week range spans $42.01 to $82.22. Analyst consensus is strong buy with an average price target of $84.48. Rallies surfaces HALO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns HALO stock?

Hedge funds tracked by Rallies that own HALO include Bridgewater Associates and Pinebridge Investments. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Halozyme Therapeutics, Inc..

HALO Key Metrics

Key financial metrics for HALO
Metric	Value
Price	$69.47
Market Cap	$8.00B
P/E Ratio	23.31
EPS	$2.96
Dividend Yield	0.00%
52-Week High	$82.22
52-Week Low	$42.01
Volume	266
Avg Volume	0
Revenue (TTM)	$1.51B
Net Income	$348.84M
Gross Margin	82.79%

Top Hedge Funds Holding HALO

Bridgewater Associates holds 511.43K shares of HALO, changed -8.93% as of Mar 31, 2026.
Pinebridge Investments holds 11.61K shares of HALO, changed +1.29% as of Sep 30, 2025.

Latest HALO News

Halozyme Reports Flat Q1 Revenues and Wider Loss; ENHANZE Deals Progress — May 11, 2026
Halozyme Reports Q1 Revenue Up 42% to $377M, Launches $1B Buyback — May 11, 2026
Halozyme Signs GSK Deal for Subcutaneous ADC Delivery, First Trial in 2026 — May 7, 2026
Halozyme’s FY2025 Royalties Up 52%, Forecasts 30-35% Growth and Licenses Hypercon to Oruka — May 6, 2026
Halozyme rises ahead of Q1 results as ENHANZE royalty outlook stays in focus — May 5, 2026

Recent HALO Insider Trades

Torley Helen sold 2.10K (~$143.01K) on May 13, 2026.
Torley Helen sold 3.35K (~$230.75K) on May 13, 2026.
Torley Helen sold 3.95K (~$275.66K) on May 13, 2026.

HALO Analyst Consensus

5 analysts cover HALO: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $84.48.

Common questions about HALO

Who owns HALO stock?: Hedge funds tracked by Rallies that own HALO include Bridgewater Associates and Pinebridge Investments. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Halozyme Therapeutics, Inc..
Does Rallies show 13F holders for HALO?: Yes. Rallies tracks hedge fund and 13F ownership data for HALO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is HALO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for HALO. It does not provide personalized investment advice.